SARS-CoV-2 variants from mink evade inhibition by antibodies
Por um escritor misterioso
Descrição
It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals. Mutations were acquired in the spike protein, which is crucial for the entry of the virus into host cells and represents the central point of attack for antibodies. These SARS-CoV-2 variants from mink were transmitted back to humans, raising concerns that minks could be a continuing source of infection of humans with SARS-CoV-2 variants with altered biological properties. Researchers at the German Primate Center (DPZ) - Leibniz Institute for Primate Research in Göttingen, Germany, have now shown that an antibody used for COVID-19 therapy is unable to effectively inhibit SARS-CoV-2 harboring a spike mutation acquired in minks. In addition, the mutation reduced the inhibition of the virus by antibodies produced in SARS-CoV-2 infected humans. These results show that SARS-CoV-2 can acquire mutations in minks that may reduce control of the virus by the human immune system. The study and findings have been published in Cell Reports.
White-tailed deer (Odocoileus virginianus) may serve as a wildlife reservoir for nearly extinct SARS-CoV-2 variants of concern
A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
COVID-19 - Wikipedia
Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
SARS-CoV-2 variant B.1.617 attacks immune system
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination - ScienceDirect
Deutsches Primatenzentrum: SARS-CoV-2 variants from mink evade inhibition by antibodies
Viruses, Free Full-Text
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
SARS-CoV-2 variants, spike mutations and immune escape
Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody
Your Reagent Warehouse for COVID-19 Vaccine Development - ACROBiosystems
Frontiers A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
de
por adulto (o preço varia de acordo com o tamanho do grupo)
